Cargando…

Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with marked oxidative stress at the level of the brain. Recent studies indicate that increasing the antioxidant capacity could represent a very promising therapeutic strategy for AD treatment. Astaxanthin (AST), a powerful natural a...

Descripción completa

Detalles Bibliográficos
Autores principales: Santonocito, Debora, Raciti, Giuseppina, Campisi, Agata, Sposito, Giovanni, Panico, Annamaria, Siciliano, Edy Angela, Sarpietro, Maria Grazia, Damiani, Elisabetta, Puglia, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913486/
https://www.ncbi.nlm.nih.gov/pubmed/33546352
http://dx.doi.org/10.3390/nano11020391
_version_ 1783656813137231872
author Santonocito, Debora
Raciti, Giuseppina
Campisi, Agata
Sposito, Giovanni
Panico, Annamaria
Siciliano, Edy Angela
Sarpietro, Maria Grazia
Damiani, Elisabetta
Puglia, Carmelo
author_facet Santonocito, Debora
Raciti, Giuseppina
Campisi, Agata
Sposito, Giovanni
Panico, Annamaria
Siciliano, Edy Angela
Sarpietro, Maria Grazia
Damiani, Elisabetta
Puglia, Carmelo
author_sort Santonocito, Debora
collection PubMed
description Alzheimer’s disease (AD) is a neurodegenerative disorder associated with marked oxidative stress at the level of the brain. Recent studies indicate that increasing the antioxidant capacity could represent a very promising therapeutic strategy for AD treatment. Astaxanthin (AST), a powerful natural antioxidant, could be a good candidate for AD treatment, although its use in clinical practice is compromised by its high instability. In order to overcome this limit, our attention focused on the development of innovative AST-loaded stealth lipid nanoparticles (AST-SSLNs) able to improve AST bioavailability in the brain. AST-SSLNs prepared by solvent-diffusion technique showed technological parameters suitable for parenteral administration (<200 nm). Formulated nanosystems were characterized by calorimetric studies, while their toxicological profile was evaluated by the MTT assay on the stem cell line OECs (Olfactory Ensheathing Cells). Furthemore, the protective effect of the nanocarriers was assessed by a long-term stability study and a UV stability assay confirming that the lipid shell of the nanocarriers was able to preserve AST concentration in the formulation. SSLNs were also capable of preserving AST’s antioxidant capacity as demonstrated in the oxygen radical absorbance capacity (ORAC) assay. In conclusion, these preliminary studies outline that SSLNs could be regarded as promising carriers for systemic administration of compounds such as AST aimed at AD treatment.
format Online
Article
Text
id pubmed-7913486
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79134862021-02-28 Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization Santonocito, Debora Raciti, Giuseppina Campisi, Agata Sposito, Giovanni Panico, Annamaria Siciliano, Edy Angela Sarpietro, Maria Grazia Damiani, Elisabetta Puglia, Carmelo Nanomaterials (Basel) Article Alzheimer’s disease (AD) is a neurodegenerative disorder associated with marked oxidative stress at the level of the brain. Recent studies indicate that increasing the antioxidant capacity could represent a very promising therapeutic strategy for AD treatment. Astaxanthin (AST), a powerful natural antioxidant, could be a good candidate for AD treatment, although its use in clinical practice is compromised by its high instability. In order to overcome this limit, our attention focused on the development of innovative AST-loaded stealth lipid nanoparticles (AST-SSLNs) able to improve AST bioavailability in the brain. AST-SSLNs prepared by solvent-diffusion technique showed technological parameters suitable for parenteral administration (<200 nm). Formulated nanosystems were characterized by calorimetric studies, while their toxicological profile was evaluated by the MTT assay on the stem cell line OECs (Olfactory Ensheathing Cells). Furthemore, the protective effect of the nanocarriers was assessed by a long-term stability study and a UV stability assay confirming that the lipid shell of the nanocarriers was able to preserve AST concentration in the formulation. SSLNs were also capable of preserving AST’s antioxidant capacity as demonstrated in the oxygen radical absorbance capacity (ORAC) assay. In conclusion, these preliminary studies outline that SSLNs could be regarded as promising carriers for systemic administration of compounds such as AST aimed at AD treatment. MDPI 2021-02-03 /pmc/articles/PMC7913486/ /pubmed/33546352 http://dx.doi.org/10.3390/nano11020391 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Santonocito, Debora
Raciti, Giuseppina
Campisi, Agata
Sposito, Giovanni
Panico, Annamaria
Siciliano, Edy Angela
Sarpietro, Maria Grazia
Damiani, Elisabetta
Puglia, Carmelo
Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization
title Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization
title_full Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization
title_fullStr Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization
title_full_unstemmed Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization
title_short Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization
title_sort astaxanthin-loaded stealth lipid nanoparticles (ast-ssln) as potential carriers for the treatment of alzheimer’s disease: formulation development and optimization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913486/
https://www.ncbi.nlm.nih.gov/pubmed/33546352
http://dx.doi.org/10.3390/nano11020391
work_keys_str_mv AT santonocitodebora astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization
AT racitigiuseppina astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization
AT campisiagata astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization
AT spositogiovanni astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization
AT panicoannamaria astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization
AT sicilianoedyangela astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization
AT sarpietromariagrazia astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization
AT damianielisabetta astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization
AT pugliacarmelo astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization